Giedre Silkuniene

Dr. Giedre Silkuniene

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Bioelectrochemistry
Verified
Journal Article
Closed access
CMClaudia Muratori
Claudia Muratori
GSGiedre Silkuniene
Giedre Silkuniene
PMPeter Mollica
Peter Mollica
APAndrei G. Pakhomov
Andrei G. Pakhomov
OPOlga Pakhomova
Olga Pakhomova

Verified
Journal Article
Open access
PDF file
GSGiedre Silkuniene
Giedre Silkuniene
UMUma Maheswari Mangalanathan
Uma Maheswari Mangalanathan
ARAlessandra Rossi
Alessandra Rossi
PMPeter Mollica
Peter Mollica
Andrei PakhomovAndrei Pakhomov
Andrei Pakhomov
OPOlga Pakhomova
Olga Pakhomova
The study was aimed at identifying endogenous proteins which assist or impede the permeabilized state in the cell membrane disrupted by nsEP (20 or 40 pulses, 300 ns width, 7 kV/cm). We employed a LentiArray CRISPR library to generate knockouts (KOs) of 316 genes encoding for membrane proteins in U937 human monocytes stably expressing Cas9 nuclease. The extent of membrane permeabilization by nsEP was measured by the uptake of Yo-Pro-1 (YP) dye and compared to sham-exposed KOs and control cells transduced with a non-targeting (scrambled) gRNA. Only two KOs, for SCNN1A and CLCA1 genes, showed a statistically significant reduction in YP uptake. The respective proteins could be part of electropermeabilization lesions or increase their lifespan. In contrast, as many as 39 genes were identified as likely hits for the increased YP uptake, meaning that the respective proteins contributed to membrane stability or repair after nsEP. The expression level of eight genes in different types of human cells showed strong correlation (R > 0.9, p < 0.02) with their LD50 for lethal nsEP treatments, and could potentially be used as a criterion for the selectivity and efficiency of hyperplasia ablations with nsEP.

5 August 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
GSGiedre Silkuniene
Giedre Silkuniene
UMUma Maheswari Mangalanathan
Uma Maheswari Mangalanathan
APAndrei G. Pakhomov
Andrei G. Pakhomov
OPOlga Pakhomova
Olga Pakhomova

Verified
Journal Article
Open access
PDF file
OPOlga Pakhomova
Olga Pakhomova
EZELENI ZIVLA
ELENI ZIVLA
GSGiedre Silkuniene
Giedre Silkuniene
MŠMantas Šilkūnas
Mantas Šilkūnas
Andrei PakhomovAndrei Pakhomov
Andrei Pakhomov
Gelonin is a ribosome-inactivating protein with extreme intracellular toxicity but poor permeation into cells. Targeted disruption of cell membranes to facilitate gelonin entry is explored for cancer and tissue ablation. We demonstrate a hundreds- to thousands-fold enhancement of gelonin cytotoxicity by pulsed electric fields in the T24, U-87, and CT26 cell lines. The effective gelonin concentration to kill 50% of cells (EC50) after electroporation ranged from <1 nM to about 100 nM. For intact cells, the EC50 was unattainable even at the highest gelonin concentration of 1000 nM, which reduced cell survival by only 5–15%. For isoeffective electroporation treatments using 300 ns, 9 µs, and 100 µs pulses, longer pulses were more efficient at lowering gelonin EC50. Increasing the electric field strength of 8, 100 µs pulses from 0.65 to 1.25 kV/cm reduced gelonin EC50 from 128 nM to 0.72 nM. Conversely, the presence of 100 nM gelonin enabled a more than 20-fold reduction in the number of pulses required for equivalent cell killing. Pulsed electric field-mediated delivery of gelonin shows promise for hyperplasia ablation at concentrations sufficiently low to minimize or avoid systemic toxicity.

10 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Pavel A. SolopovPavel A. Solopov
Pavel A. Solopov
AEAlayna L Enos
Alayna L Enos
MŠMantas Šilkūnas
Mantas Šilkūnas
GSGiedre Silkuniene
Giedre Silkuniene
EZELENI ZIVLA
ELENI ZIVLA
OPOlga Pakhomova
Olga Pakhomova
Background/Objectives: Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with poor prognosis and limited treatment options, highlighting the need for reliable preclinical models for translational research. Although xenograft models are widely used in cancer biology, systematic characterization of subcutaneous ESCC models under defined implantation conditions remains limited. The objective of this study was to systematically compare implantation conditions and define histopathological and growth-related parameters that enable reproducible tumor establishment while maintaining a practical experimental window for therapeutic studies. Methods: We established and characterized a subcutaneous ESCC xenograft model using human ESCC cell line KYSE-30 implanted into immunodeficient J:NU mice. Tumor growth dynamics were compared under three implantation conditions: cells suspended in phosphate-buffered saline (PBS), Matrigel (Corning, basement membrane matrix), or Matrigel diluted with PBS. Results: Tumors generated from Matrigel-embedded cells exhibited rapid growth, reaching substantial size within approximately one week after implantation, which limited their utility for controlled therapeutic studies. In contrast, tumors generated from cells suspended in Matrigel + PBS demonstrated slower but consistent expansion, providing a more suitable and reproducible experimental window for therapeutic intervention. Cells injected in PBS alone showed inefficient tumor establishment. Histopathologic and immunohistochemical analyses revealed matrix-dependent differences in necrosis, stromal organization, and proliferative activity, while confirming epithelial tumor identity and baseline vascularization. Conclusions: Collectively, these findings define a reproducible KYSE-30 subcutaneous xenograft model and identify Matrigel dilution with PBS as an optimal implantation strategy that balances reliable tumor engraftment with controlled tumor growth suitable for therapeutic studies.